Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12401611,FIO(2),"After intubation of the trachea, the lungs of the patients were ventilated to normocapnia with an oxygen-air mixture (FIO(2) = 0.33).",Changes of propofol concentration in cerebrospinal fluid during continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401611/),,0.33,394,DB00565,Cisatracurium besylate
,12401611,concentration,The CSF propofol concentration at 180 min (21.4 +/- 14.0 ng/mL) was not significantly different from the concentration at 150 min.,Changes of propofol concentration in cerebrospinal fluid during continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401611/),[ng] / [ml],21.4,395,DB00565,Cisatracurium besylate
,8624002,Onset of,"Onset of block was delayed in the elderly; values being mean 3.0 (95% confidence interval 1.75-11.4) min and 4.0 (2.4-6.5) min in the young and elderly, respectively (P < 0.01).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),min,3.0,4027,DB00565,Cisatracurium besylate
,8624002,Onset of,"Onset of block was delayed in the elderly; values being mean 3.0 (95% confidence interval 1.75-11.4) min and 4.0 (2.4-6.5) min in the young and elderly, respectively (P < 0.01).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),min,4.0,4028,DB00565,Cisatracurium besylate
,8624002,Plasma clearance,Plasma clearance was 319 (293-345) ml/min in the study population and did not differ between young and elderly patients.,Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),[ml] / [min],319,4029,DB00565,Cisatracurium besylate
,8624002,Apparent volume of distribution,"Apparent volume of distribution was 13.28 (9.9-16.7) 1 and 9.6 (7.6-11.7) 1 in the elderly and young adults, respectively (P < 0.05).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),1,13.28,4030,DB00565,Cisatracurium besylate
,8624002,Apparent volume of distribution,"Apparent volume of distribution was 13.28 (9.9-16.7) 1 and 9.6 (7.6-11.7) 1 in the elderly and young adults, respectively (P < 0.05).",Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),1,9.6,4031,DB00565,Cisatracurium besylate
,8624002,rate of biophase equilibration (ke0),There also were differences in pharmacodynamic parameters between the young and elderly; the predominant change being a slower rate of biophase equilibration (ke0) in the elderly (0.060 [0.052-0.068])/min compared with the young (0.071 [0.065-0.077]/min; P < 0.05).,Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),,0.060,4032,DB00565,Cisatracurium besylate
,8624002,rate of biophase equilibration (ke0),There also were differences in pharmacodynamic parameters between the young and elderly; the predominant change being a slower rate of biophase equilibration (ke0) in the elderly (0.060 [0.052-0.068])/min compared with the young (0.071 [0.065-0.077]/min; P < 0.05).,Pharmacokinetics and pharmacodynamics of cisatracurium in young and elderly adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8624002/),1/[min],0.071,4033,DB00565,Cisatracurium besylate
,8659778,Onset to 90% paralysis,Onset to 90% paralysis (mean +/- SD) was delayed in the elderly (3.4 +/- 1.0 vs. 2.5 +/- 0.6 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,3.4,51558,DB00565,Cisatracurium besylate
,8659778,Onset to 90% paralysis,Onset to 90% paralysis (mean +/- SD) was delayed in the elderly (3.4 +/- 1.0 vs. 2.5 +/- 0.6 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,2.5,51559,DB00565,Cisatracurium besylate
,8659778,Elimination half-life,Elimination half-life was minimally prolonged in the elderly (25.5 +/- 3.7 vs. 21.5 +/- 2.4 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,25.5,51560,DB00565,Cisatracurium besylate
,8659778,Elimination half-life,Elimination half-life was minimally prolonged in the elderly (25.5 +/- 3.7 vs. 21.5 +/- 2.4 min).,Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,21.5,51561,DB00565,Cisatracurium besylate
,8659778,Vss,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg],126,51562,DB00565,Cisatracurium besylate
,8659778,Vss,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg],108,51563,DB00565,Cisatracurium besylate
,8659778,clearances,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg·min],5.0,51564,DB00565,Cisatracurium besylate
,8659778,clearances,"The Vss was larger in the elderly (126 +/- 16 vs. 108 +/- 13 ml/kg), although the clearances were the same for the two groups (5.0 +/- 0.9 vs. 4.6 +/- 0.8 ml.kg(-1).min(-1).",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),[ml] / [kg·min],4.6,51565,DB00565,Cisatracurium besylate
,8659778,time to onset,"These differences are not associated with changes in recovery profile after a single bolus dose, although the mean time to onset was approximately 1 min longer in elderly patients.",Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659778/),min,1,51566,DB00565,Cisatracurium besylate
> or =,8602660,train-of-four ratio,All patients were allowed to recover spontaneously to a train-of-four ratio > or = 0.70 after cisatracurium-induced neuromuscular block.,Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),,0.70,54591,DB00565,Cisatracurium besylate
,8602660,clearances,The clearances (5.28 +/- 1.23 vs.,Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),,5.28,54592,DB00565,Cisatracurium besylate
,8602660,terminal elimination half-lives,"4.66 +/- 0.67 ml x min(-1) x kg(-1) and terminal elimination half-lives (22.4 +/- 2.7 vs. 25.5 +/- 4.1 min) were not statistically different between patients receiving 0.1 mg x kg(-1) and 0.2 mg x kg(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),min,22.4,54593,DB00565,Cisatracurium besylate
,8602660,terminal elimination half-lives,"4.66 +/- 0.67 ml x min(-1) x kg(-1) and terminal elimination half-lives (22.4 +/- 2.7 vs. 25.5 +/- 4.1 min) were not statistically different between patients receiving 0.1 mg x kg(-1) and 0.2 mg x kg(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),min,25.5,54594,DB00565,Cisatracurium besylate
,8602660,Maximum concentration,"Maximum concentration values for laudanosine averaged 38 +/- 21 and 103 +/- 34 ng x ml(-1) for patients receiving the 0.1 and 0.2 mg x kg(-1) doses, respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],38,54595,DB00565,Cisatracurium besylate
,8602660,Maximum concentration,"Maximum concentration values for laudanosine averaged 38 +/- 21 and 103 +/- 34 ng x ml(-1) for patients receiving the 0.1 and 0.2 mg x kg(-1) doses, respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],103,54596,DB00565,Cisatracurium besylate
,8602660,Maximum concentration,"Maximum concentration values for monoquaternary alcohol averaged 101 +/- 27 and 253 +/- 51 ng x ml(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],101,54597,DB00565,Cisatracurium besylate
,8602660,Maximum concentration,"Maximum concentration values for monoquaternary alcohol averaged 101 +/- 27 and 253 +/- 51 ng x ml(-1), respectively.",Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602660/),[ng] / [ml],253,54598,DB00565,Cisatracurium besylate
,22114771,Steady-state volume of distribution,Steady-state volume of distribution was determined to be 111 ± 71 ml kg(-1) and plasma clearance was 5.2 ± 1.8 ml min(-1) kg(-1) in these patients with greater inter-patient variability compared with other populations.,The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114771/),[ml] / [kg],111,61087,DB00565,Cisatracurium besylate
,22114771,plasma clearance,Steady-state volume of distribution was determined to be 111 ± 71 ml kg(-1) and plasma clearance was 5.2 ± 1.8 ml min(-1) kg(-1) in these patients with greater inter-patient variability compared with other populations.,The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114771/),[ml] / [kg·min],5.2,61088,DB00565,Cisatracurium besylate
,22114771,time to maximum block,"The time to maximum block (8.3 ± 2.9 min) and delay time of transferring from central to effect compartment (17.2 min) was much longer, while the maximum block (95.0 ± 6.3%) was less compared with those in other patient populations.",The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114771/),min,8.3,61089,DB00565,Cisatracurium besylate
,22114771,time of transferring from central to effect compartment,"The time to maximum block (8.3 ± 2.9 min) and delay time of transferring from central to effect compartment (17.2 min) was much longer, while the maximum block (95.0 ± 6.3%) was less compared with those in other patient populations.",The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114771/),min,17.2,61090,DB00565,Cisatracurium besylate
,22114771,effect compartment concentration resulting in,The effect compartment concentration resulting in 50% of maximum effect (128 ± 58 ng ml(-1)) was larger than previously described.,The pharmacokinetics and pharmacodynamics of cisatracurium in critically ill patients with severe sepsis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22114771/),[ng] / [ml],128,61091,DB00565,Cisatracurium besylate
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,2.2,80742,DB00565,Cisatracurium besylate
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,3.4,80743,DB00565,Cisatracurium besylate
,9349062,times to 90%,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,1.3,80744,DB00565,Cisatracurium besylate
,9349062,maximum depression of the first twitch,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,3.4,80745,DB00565,Cisatracurium besylate
,9349062,maximum depression of the first twitch,"The times to 90% and maximum depression of the first twitch of the train-of-four were significantly longer after cisatracurium than atracurium (2.2 and 3.4 min compared with 1.3 and 1.8 min, respectively; p < 0.01 in each instance).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,1.8,80746,DB00565,Cisatracurium besylate
,9349062,clearance,"The different isomer groups of atracurium have different pharmacokinetics, the trans-trans group having the highest clearance (1440 ml.min-1) and the cis-cis group the lowest (499 ml.min-1).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],1440,80747,DB00565,Cisatracurium besylate
,9349062,clearance,"The different isomer groups of atracurium have different pharmacokinetics, the trans-trans group having the highest clearance (1440 ml.min-1) and the cis-cis group the lowest (499 ml.min-1).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],499,80748,DB00565,Cisatracurium besylate
,9349062,clearance,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),[ml] / [min],425,80749,DB00565,Cisatracurium besylate
,9349062,elimination half-life,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,34.9,80750,DB00565,Cisatracurium besylate
,9349062,elimination half-life,"The clearance of cisatracurium (425 ml.min-1) is less than that of cis-cis atracurium and its elimination half-life is longer (34.9 min and 21.9 min, respectively).","A comparison of the infusion pharmacokinetics and pharmacodynamics of cisatracurium, the 1R-cis 1'R-cis isomer of atracurium, with atracurium besylate in healthy patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349062/),min,21.9,80751,DB00565,Cisatracurium besylate
,8785138,infusion time,"The mean infusion time in group 1 was 37.6 h and in group 2, 27.5 h.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),h,37.6,90953,DB00565,Cisatracurium besylate
,8785138,infusion time,"The mean infusion time in group 1 was 37.6 h and in group 2, 27.5 h.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),h,27.5,90954,DB00565,Cisatracurium besylate
,8785138,time for the TOF ratio,"On termination of the infusion, the time for the TOF ratio to reach 0.7 was similar in the two groups (group 1 = 60 min; group 2 = 62 min).",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,0.7,90955,DB00565,Cisatracurium besylate
,8785138,time for the TOF ratio,"On termination of the infusion, the time for the TOF ratio to reach 0.7 was similar in the two groups (group 1 = 60 min; group 2 = 62 min).",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,60,90956,DB00565,Cisatracurium besylate
,8785138,time for the TOF ratio,"On termination of the infusion, the time for the TOF ratio to reach 0.7 was similar in the two groups (group 1 = 60 min; group 2 = 62 min).",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,62,90957,DB00565,Cisatracurium besylate
,8785138,infusion rate,The mean infusion rate of cis-atracurium was 0.19 mg kg-1 h-1 and of atracurium 0.47 mg kg-1 h-1 (expressed as mg of bis-cation): cis-atracurium was 2.5 times more potent than atracurium.,Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[mg] / [h·kg],0.19,90958,DB00565,Cisatracurium besylate
,8785138,infusion rate,The mean infusion rate of cis-atracurium was 0.19 mg kg-1 h-1 and of atracurium 0.47 mg kg-1 h-1 (expressed as mg of bis-cation): cis-atracurium was 2.5 times more potent than atracurium.,Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[mg] / [h·kg],0.47,90959,DB00565,Cisatracurium besylate
,8785138,volume of distribution (V),"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),ml,"21,900",90960,DB00565,Cisatracurium besylate
,8785138,clearance (Cl),"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[ml] / [min],549,90961,DB00565,Cisatracurium besylate
,8785138,half-life (T1/2),"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,27.6,90962,DB00565,Cisatracurium besylate
,8785138,V,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),ml,"15,100",90963,DB00565,Cisatracurium besylate
,8785138,Cl,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[ml] / [min],449,90964,DB00565,Cisatracurium besylate
,8785138,T1/2,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,23.4,90965,DB00565,Cisatracurium besylate
,8785138,V,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),ml,"18,000",90966,DB00565,Cisatracurium besylate
,8785138,Cl,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[ml] / [min],1070,90967,DB00565,Cisatracurium besylate
,8785138,T1/2,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),,11.7,90968,DB00565,Cisatracurium besylate
,8785138,V,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),ml,"13,100",90969,DB00565,Cisatracurium besylate
,8785138,Cl,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[ml] / [min],1560,90970,DB00565,Cisatracurium besylate
,8785138,T1/2,"The mean population pharmacokinetic values for cis-atracurium were: volume of distribution (V) = 21,900 (SEM 416) ml; clearance (Cl) = 549 (79) ml min-1; half-life (T1/2) = 27.6 (3.6) min; and for the three groups of atracurium isomers were: cis-cis, V = 15,100 (720) ml, Cl = 449 (42) ml min-1, T1/2 = 23.4 (1.2) min; cis-trans, V = 18,000 (667) ml, Cl = 1070 (43) ml min-1, T1/2 = 11.7 (0.1); trans-trans, V = 13,100 (1280) ml, Cl = 1560 (55) ml min-1, T1/2 = 5.8 (0.4) min.",Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),min,5.8,90971,DB00565,Cisatracurium besylate
,8785138,peak value,Plasma laudanosine concentrations were lower in the cis-atracurium (peak value 1.3 micrograms ml-1) than in the atracurium (maximum 4.4 micrograms ml-1) group.,Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[μg] / [ml],1.3,90972,DB00565,Cisatracurium besylate
,8785138,peak value,Plasma laudanosine concentrations were lower in the cis-atracurium (peak value 1.3 micrograms ml-1) than in the atracurium (maximum 4.4 micrograms ml-1) group.,Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[μg] / [ml],4.4,90973,DB00565,Cisatracurium besylate
,8785138,maximum,Plasma laudanosine concentrations were lower in the cis-atracurium (peak value 1.3 micrograms ml-1) than in the atracurium (maximum 4.4 micrograms ml-1) group.,Comparison of the pharmacodynamics and pharmacokinetics of an infusion of cis-atracurium (51W89) or atracurium in critically ill patients undergoing mechanical ventilation in an intensive therapy unit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785138/),[μg] / [ml],4.4,90974,DB00565,Cisatracurium besylate
,15505447,recovery time,The median recovery time for train-of-four for cisatracurium (30 min) was less than that for vecuronium (180 min) (P < 0.05).,Comparison of cisatracurium and vecuronium by infusion in neonates and small infants after congenital heart surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505447/),min,30,108572,DB00565,Cisatracurium besylate
,15505447,recovery time,The median recovery time for train-of-four for cisatracurium (30 min) was less than that for vecuronium (180 min) (P < 0.05).,Comparison of cisatracurium and vecuronium by infusion in neonates and small infants after congenital heart surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505447/),min,180,108573,DB00565,Cisatracurium besylate
,15673889,clearance,"The clearance of cisatracurium was significantly faster in Group A when compared with Group C (7.12 +/- 1.87 versus 5.72 +/- 0.70 L . kg(-1) . min(-1), P = 0.01).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[l] / [kg·min],7.12,113790,DB00565,Cisatracurium besylate
,15673889,clearance,"The clearance of cisatracurium was significantly faster in Group A when compared with Group C (7.12 +/- 1.87 versus 5.72 +/- 0.70 L . kg(-1) . min(-1), P = 0.01).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[l] / [kg·min],5.72,113791,DB00565,Cisatracurium besylate
,15673889,Cp(ss)95,"The Cp(ss)95 was also significantly larger in Group A (191 +/- 45 versus 159 +/- 36 ng/mL, P = 0.04).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[ng] / [ml],191,113792,DB00565,Cisatracurium besylate
,15673889,Cp(ss)95,"The Cp(ss)95 was also significantly larger in Group A (191 +/- 45 versus 159 +/- 36 ng/mL, P = 0.04).",Cisatracurium-induced neuromuscular blockade is affected by chronic phenytoin or carbamazepine treatment in neurosurgical patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15673889/),[ng] / [ml],159,113793,DB00565,Cisatracurium besylate
,11473869,plasma concentration,"The plasma concentration of cisatracurium during the infusion averaged 1.00 (0.25-1.45) microg/mL, expressed as median (range).",The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473869/),[μg] / [ml],1.00,123156,DB00565,Cisatracurium besylate
,11473869,clearance,The clearance and half-life were 6.5 (3.3-7.6) mL. min(-1).,The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473869/),[ml] / [min],6.5,123157,DB00565,Cisatracurium besylate
,11473869,plasma concentrations,The laudanosine plasma concentrations were 0.70 (0.12-1.20) microg/mL.,The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11473869/),[μg] / [ml],0.70,123158,DB00565,Cisatracurium besylate
,20444012,terminal elimination rate,Mean in vivo terminal elimination rate of cisatracurium (16.4 +/- 2.7 min) was twofold faster than mean in vitro degradation rate (32.9 +/- 3.7 min) in our dogs.,Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),min,16.4,129247,DB00565,Cisatracurium besylate
,20444012,degradation rate,Mean in vivo terminal elimination rate of cisatracurium (16.4 +/- 2.7 min) was twofold faster than mean in vitro degradation rate (32.9 +/- 3.7 min) in our dogs.,Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),min,32.9,129248,DB00565,Cisatracurium besylate
,20444012,Organ clearance,Organ clearance was 6.12 +/- 1.69 mL/min.kg and accounted for 56 +/- 12% of the total body clearance.,Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),[ml] / [kg·min],6.12,129249,DB00565,Cisatracurium besylate
,20444012,Apparent volume of distribution,"Apparent volume of distribution, an exit site-dependent parameter, averaged 212 or 184 mL/kg whether or not peripheral elimination was accounted for in the model.",Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),[ml] / [kg],212,129250,DB00565,Cisatracurium besylate
,20444012,Apparent volume of distribution,"Apparent volume of distribution, an exit site-dependent parameter, averaged 212 or 184 mL/kg whether or not peripheral elimination was accounted for in the model.",Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),[ml] / [kg],184,129251,DB00565,Cisatracurium besylate
,27582302,time to the maximal neuromuscular blocking effect,The time to the maximal neuromuscular blocking effect of cisatracurium was delayed in the MR group (2.08 min in the control group vs. 4.12 min in the MR group).,Altered pharmacodynamics and pharmacokinetics of cisatracurium in patients with severe mitral valve regurgitation during anaesthetic induction period. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27582302/),min,2.08,133757,DB00565,Cisatracurium besylate
,27582302,time to the maximal neuromuscular blocking effect,The time to the maximal neuromuscular blocking effect of cisatracurium was delayed in the MR group (2.08 min in the control group vs. 4.12 min in the MR group).,Altered pharmacodynamics and pharmacokinetics of cisatracurium in patients with severe mitral valve regurgitation during anaesthetic induction period. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27582302/),min,4.12,133758,DB00565,Cisatracurium besylate
,15190236,Fi O2,After tracheal intubation the lungs were ventilated to achieve normocapnia with an oxygen-air mixture (Fi O2 = 0.33).,Relationships between total and unbound propofol in plasma and CSF during continuous drug infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15190236/),,0.33,139755,DB00565,Cisatracurium besylate
,9806701,elimination rate constant,The elimination rate constant from the peripheral compartment was fixed to the in vitro rate of degradation of cisatracurium in human plasma (0.0237 min(-1)).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.0237,145684,DB00565,Cisatracurium besylate
,9806701,rate of degradation,The elimination rate constant from the peripheral compartment was fixed to the in vitro rate of degradation of cisatracurium in human plasma (0.0237 min(-1)).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.0237,145685,DB00565,Cisatracurium besylate
,9806701,terminal half-life,"The mean terminal half-life of cisatracurium was 23.9+/-3.3 min, and its total clearance averaged 3.7+/-0.8 mL x min(-1) x kg(-1).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),min,23.9,145686,DB00565,Cisatracurium besylate
,9806701,total clearance,"The mean terminal half-life of cisatracurium was 23.9+/-3.3 min, and its total clearance averaged 3.7+/-0.8 mL x min(-1) x kg(-1).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[ml] / [kg·min],3.7,145687,DB00565,Cisatracurium besylate
,9806701,volume of distribution at steady state,"Using this model, the volume of distribution at steady state was significantly increased compared with that obtained when central elimination only was assumed (0.118+/-0.027 vs 0.089+/-0.017 L/kg).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[l] / [kg],0.118,145688,DB00565,Cisatracurium besylate
,9806701,volume of distribution at steady state,"Using this model, the volume of distribution at steady state was significantly increased compared with that obtained when central elimination only was assumed (0.118+/-0.027 vs 0.089+/-0.017 L/kg).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[l] / [kg],0.089,145689,DB00565,Cisatracurium besylate
,9806701,rate constant,The effect-plasma equilibration rate constant was 0.054+/-0.013 min(-1).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.054,145690,DB00565,Cisatracurium besylate
,9806701,50% effective concentration,"The 50% effective concentration (153+/-33 ng/mL) was 56% higher than that reported in patients anesthetized with volatile anesthetics, which suggests that, compared with inhaled anesthetics, a cisatracurium neuromuscular block is less enhanced by propofol.",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[ng] / [ml],153,145691,DB00565,Cisatracurium besylate
,23698546,Central,"Central and steady state apparent volumes of distribution (V1, Vdss) and slope factor (γ) were larger, effect-compartment concentration at 50% neuromuscular block was lower in the ANH (90.8±41.6 mL kg-1, 159.1±39.2 mL kg-1, 6.0±0.9 and 136.4±29.1 ng·mL-1) compared with the control group (65.5±26.1 mL kg-1, 134.8±31.8 mL kg-1, 5.5±0.8 and 158.5±26.0 ng·mL-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg],90.8,151983,DB00565,Cisatracurium besylate
,23698546,"steady state apparent volumes of distribution (V1, Vdss)","Central and steady state apparent volumes of distribution (V1, Vdss) and slope factor (γ) were larger, effect-compartment concentration at 50% neuromuscular block was lower in the ANH (90.8±41.6 mL kg-1, 159.1±39.2 mL kg-1, 6.0±0.9 and 136.4±29.1 ng·mL-1) compared with the control group (65.5±26.1 mL kg-1, 134.8±31.8 mL kg-1, 5.5±0.8 and 158.5±26.0 ng·mL-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg],159.1,151984,DB00565,Cisatracurium besylate
,23698546,"steady state apparent volumes of distribution (V1, Vdss)","Central and steady state apparent volumes of distribution (V1, Vdss) and slope factor (γ) were larger, effect-compartment concentration at 50% neuromuscular block was lower in the ANH (90.8±41.6 mL kg-1, 159.1±39.2 mL kg-1, 6.0±0.9 and 136.4±29.1 ng·mL-1) compared with the control group (65.5±26.1 mL kg-1, 134.8±31.8 mL kg-1, 5.5±0.8 and 158.5±26.0 ng·mL-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ng] / [ml],6.0,151985,DB00565,Cisatracurium besylate
,23698546,"steady state apparent volumes of distribution (V1, Vdss)","Central and steady state apparent volumes of distribution (V1, Vdss) and slope factor (γ) were larger, effect-compartment concentration at 50% neuromuscular block was lower in the ANH (90.8±41.6 mL kg-1, 159.1±39.2 mL kg-1, 6.0±0.9 and 136.4±29.1 ng·mL-1) compared with the control group (65.5±26.1 mL kg-1, 134.8±31.8 mL kg-1, 5.5±0.8 and 158.5±26.0 ng·mL-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg],134.8,151986,DB00565,Cisatracurium besylate
,23698546,slope factor (γ),"Central and steady state apparent volumes of distribution (V1, Vdss) and slope factor (γ) were larger, effect-compartment concentration at 50% neuromuscular block was lower in the ANH (90.8±41.6 mL kg-1, 159.1±39.2 mL kg-1, 6.0±0.9 and 136.4±29.1 ng·mL-1) compared with the control group (65.5±26.1 mL kg-1, 134.8±31.8 mL kg-1, 5.5±0.8 and 158.5±26.0 ng·mL-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg],134.8,151987,DB00565,Cisatracurium besylate
,23698546,Elimination half-life (t1/2 β),"Elimination half-life (t1/2 β) and mean residence time (MRT) were longer in the ANH (37.2±20.9, 23.5±13.2 min) than the control group (26.8±9.8, 16.9±6.2 min), albeit not statistically significant (P=0.051, P=0.051).",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,37.2,151988,DB00565,Cisatracurium besylate
,23698546,Elimination half-life (t1/2 β),"Elimination half-life (t1/2 β) and mean residence time (MRT) were longer in the ANH (37.2±20.9, 23.5±13.2 min) than the control group (26.8±9.8, 16.9±6.2 min), albeit not statistically significant (P=0.051, P=0.051).",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,26.8,151989,DB00565,Cisatracurium besylate
,23698546,mean residence time (MRT),"Elimination half-life (t1/2 β) and mean residence time (MRT) were longer in the ANH (37.2±20.9, 23.5±13.2 min) than the control group (26.8±9.8, 16.9±6.2 min), albeit not statistically significant (P=0.051, P=0.051).",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,23.5,151990,DB00565,Cisatracurium besylate
,23698546,mean residence time (MRT),"Elimination half-life (t1/2 β) and mean residence time (MRT) were longer in the ANH (37.2±20.9, 23.5±13.2 min) than the control group (26.8±9.8, 16.9±6.2 min), albeit not statistically significant (P=0.051, P=0.051).",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,26.8,151991,DB00565,Cisatracurium besylate
,23698546,mean residence time (MRT),"Elimination half-life (t1/2 β) and mean residence time (MRT) were longer in the ANH (37.2±20.9, 23.5±13.2 min) than the control group (26.8±9.8, 16.9±6.2 min), albeit not statistically significant (P=0.051, P=0.051).",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,16.9,151992,DB00565,Cisatracurium besylate
,23698546,distribution half-life (t1/2 α),"There were no significant differences in distribution half-life (t1/2 α), effect-compartment equilibration rate-constant (keo), central and total clearances (Clc, Cl) between the ANH (2.4±1.2 min, 0.070±0.013 min-1, 6.1±1.9 mL kg-1 min-1 and 7.7±2.3 mL kg-1 min-1) and control group (1.9±1.2 min, 0.063±0.008 min-1, 7.0±1.8 mL kg-1 min-1 and 8.5±2.1 mL kg-1 min-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),min,2.4,151993,DB00565,Cisatracurium besylate
,23698546,"total clearances (Clc, Cl)","There were no significant differences in distribution half-life (t1/2 α), effect-compartment equilibration rate-constant (keo), central and total clearances (Clc, Cl) between the ANH (2.4±1.2 min, 0.070±0.013 min-1, 6.1±1.9 mL kg-1 min-1 and 7.7±2.3 mL kg-1 min-1) and control group (1.9±1.2 min, 0.063±0.008 min-1, 7.0±1.8 mL kg-1 min-1 and 8.5±2.1 mL kg-1 min-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg·min],6.1,151994,DB00565,Cisatracurium besylate
,23698546,"total clearances (Clc, Cl)","There were no significant differences in distribution half-life (t1/2 α), effect-compartment equilibration rate-constant (keo), central and total clearances (Clc, Cl) between the ANH (2.4±1.2 min, 0.070±0.013 min-1, 6.1±1.9 mL kg-1 min-1 and 7.7±2.3 mL kg-1 min-1) and control group (1.9±1.2 min, 0.063±0.008 min-1, 7.0±1.8 mL kg-1 min-1 and 8.5±2.1 mL kg-1 min-1) respectively.",Influence of acute normovolemic hemodilution on the pharmacokinetics of Cisatracurium Besylate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23698546/),[ml] / [kg·min],7.7,151995,DB00565,Cisatracurium besylate
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],136,191220,DB00565,Cisatracurium besylate
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],157,191221,DB00565,Cisatracurium besylate
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],209,191222,DB00565,Cisatracurium besylate
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0675,191223,DB00565,Cisatracurium besylate
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0568,191224,DB00565,Cisatracurium besylate
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0478,191225,DB00565,Cisatracurium besylate
,16492821,Onset time,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,2.5,197103,DB00565,Cisatracurium besylate
,16492821,recovery to 25% of baseline twitch height,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,37.6,197104,DB00565,Cisatracurium besylate
,16492821,25%-75% recovery index,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,10.9,197105,DB00565,Cisatracurium besylate
,16492821,Distribution,"Distribution and elimination half-lives were 3.5 +/- 0.9 min and 22.9 +/- 4.5 min, respectively.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,3.5,197106,DB00565,Cisatracurium besylate
,16492821,elimination half-lives,"Distribution and elimination half-lives were 3.5 +/- 0.9 min and 22.9 +/- 4.5 min, respectively.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,22.9,197107,DB00565,Cisatracurium besylate
,16492821,Steady-state volume of distribution,Steady-state volume of distribution (0.207 +/- 0.031 L/kg) and total body clearance (6.8 +/- 0.7 mL/min/kg) were significantly larger than those published for adults.,Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),[l] / [kg],0.207,197108,DB00565,Cisatracurium besylate
,16492821,total body clearance,Steady-state volume of distribution (0.207 +/- 0.031 L/kg) and total body clearance (6.8 +/- 0.7 mL/min/kg) were significantly larger than those published for adults.,Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),[ml] / [kg·min],6.8,197109,DB00565,Cisatracurium besylate
,16492821,rate constant,"Although the plasma-effect compartment equilibration rate constant was twofold faster (0.115 +/- 0.025 min(-1)) than that published for cisatracurium in adults, the effect compartment concentration corresponding to 50% block was similar (129 +/- 27 ng/mL).",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),1/[min],0.115,197110,DB00565,Cisatracurium besylate
,9989341,total body clearance (CL),"The total body clearance (CL), steady-state Vd and elimination half-life of cisatracurium besilate in patients with normal organ function are approximately 0.28 L/h/kg (4.7 ml/min/kg), 0.145 L/kg and 25 minutes, respectively.",Clinical pharmacokinetics of cisatracurium besilate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989341/),[l] / [h·kg],0.28,216468,DB00565,Cisatracurium besylate
,9989341,steady-state Vd,"The total body clearance (CL), steady-state Vd and elimination half-life of cisatracurium besilate in patients with normal organ function are approximately 0.28 L/h/kg (4.7 ml/min/kg), 0.145 L/kg and 25 minutes, respectively.",Clinical pharmacokinetics of cisatracurium besilate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989341/),[ml] / [kg·min],4.7,216469,DB00565,Cisatracurium besylate
,9989341,steady-state Vd,"The total body clearance (CL), steady-state Vd and elimination half-life of cisatracurium besilate in patients with normal organ function are approximately 0.28 L/h/kg (4.7 ml/min/kg), 0.145 L/kg and 25 minutes, respectively.",Clinical pharmacokinetics of cisatracurium besilate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989341/),[l] / [kg],0.145,216470,DB00565,Cisatracurium besylate
,9989341,elimination half-life,"The total body clearance (CL), steady-state Vd and elimination half-life of cisatracurium besilate in patients with normal organ function are approximately 0.28 L/h/kg (4.7 ml/min/kg), 0.145 L/kg and 25 minutes, respectively.",Clinical pharmacokinetics of cisatracurium besilate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989341/),min,25,216471,DB00565,Cisatracurium besylate
,8895287,Clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],5.20,217685,DB00565,Cisatracurium besylate
,8895287,Clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],4.00,217686,DB00565,Cisatracurium besylate
,8895287,Clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],1.20,217687,DB00565,Cisatracurium besylate
,8895287,Clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],0.85,217688,DB00565,Cisatracurium besylate
,8895287,total body clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],4.00,217689,DB00565,Cisatracurium besylate
,8895287,total body clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],1.20,217690,DB00565,Cisatracurium besylate
,8895287,total body clearance,"Clearance values (mean +/- SD) were 5.20 +/- 0.86, 4.00 +/- 1.04, 1.20 +/- 0.71, and 0.85 +/- 0.32 mL.min-1.kg-1 for total body clearance, Hofmann clearance, organ clearance, and renal clearance, respectively.",Importance of the organ-independent elimination of cisatracurium. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895287/),[ml] / [kg·min],0.85,217691,DB00565,Cisatracurium besylate
,25558191,Gastric pH,Gastric pH of the placebo and tramadol groups was 1.97 versus 1.98 (P = 0.092) respectively.,Effect of single oral dose of tramadol on gastric secretions pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558191/),,1.97,221407,DB00565,Cisatracurium besylate
,25558191,Gastric pH,Gastric pH of the placebo and tramadol groups was 1.97 versus 1.98 (P = 0.092) respectively.,Effect of single oral dose of tramadol on gastric secretions pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558191/),,1.98,221408,DB00565,Cisatracurium besylate
,24631811,detection limit,"The assay was linear from 50 to 2800ngmL(-1), with a detection limit of 12ngmL(-1).",High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24631811/),1/[ngml],12,232389,DB00565,Cisatracurium besylate
,24631811,recoveries,The mean recoveries were in the range of 92.1-100.4%.,High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24631811/),%,92.1-100.4,232390,DB00565,Cisatracurium besylate
less,24631811,total HPLC run time,The total HPLC run time was less than 10min.,High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24631811/),min,10,232391,DB00565,Cisatracurium besylate
,8688259,Volume of distribution at steady state,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ml] / [kg],195,235035,DB00565,Cisatracurium besylate
,8688259,Volume of distribution at steady state,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ml] / [kg],161,235036,DB00565,Cisatracurium besylate
,8688259,plasma clearance,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ml] / [kg·min],6.6,235037,DB00565,Cisatracurium besylate
,8688259,plasma clearance,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ml] / [kg·min],5.7,235038,DB00565,Cisatracurium besylate
,8688259,elimination half-lives,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,24.4,235039,DB00565,Cisatracurium besylate
,8688259,elimination half-lives,"Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,23.5,235040,DB00565,Cisatracurium besylate
,8688259,time to maximum block,"The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,2.4,235041,DB00565,Cisatracurium besylate
,8688259,time to maximum block,"The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,3.3,235042,DB00565,Cisatracurium besylate
,8688259,clinical effective duration of action (,"The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,53.5,235043,DB00565,Cisatracurium besylate
,8688259,time to 25% recovery),"The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,53.5,235044,DB00565,Cisatracurium besylate
,8688259,time to 25% recovery),"The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns).",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,46.9,235045,DB00565,Cisatracurium besylate
,8688259,recovery index,The recovery index (25-75% recovery) was also similar in both groups: 15.4 (4.2) min in liver transplant patients and 12.8 (1.9) min in control patients (ns).,Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,15.4,235046,DB00565,Cisatracurium besylate
,8688259,recovery index,The recovery index (25-75% recovery) was also similar in both groups: 15.4 (4.2) min in liver transplant patients and 12.8 (1.9) min in control patients (ns).,Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),min,12.8,235047,DB00565,Cisatracurium besylate
,8688259,peak laudanosine concentrations,"After cisatracurium, peak laudanosine concentrations were 16 (5) and 21 (5) ng ml-1 in liver transplant and control patients, respectively.",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ng] / [ml],16,235048,DB00565,Cisatracurium besylate
,8688259,peak laudanosine concentrations,"After cisatracurium, peak laudanosine concentrations were 16 (5) and 21 (5) ng ml-1 in liver transplant and control patients, respectively.",Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688259/),[ng] / [ml],21,235049,DB00565,Cisatracurium besylate
,10223167,clearance,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.16,240354,DB00565,Cisatracurium besylate
,10223167,elimination half-life,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,120,240355,DB00565,Cisatracurium besylate
,10223167,clearance,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.27,240356,DB00565,Cisatracurium besylate
,10223167,elimination half-life,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,83,240357,DB00565,Cisatracurium besylate
,10223167,clearance,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.59,240358,DB00565,Cisatracurium besylate
,10223167,elimination half-life,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,112,240359,DB00565,Cisatracurium besylate
,10223167,clearance,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.15,240360,DB00565,Cisatracurium besylate
,10223167,elimination half-life,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,87,240361,DB00565,Cisatracurium besylate
,10223167,clearance,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],4.74,240362,DB00565,Cisatracurium besylate
,10223167,elimination half-lives,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,2,240363,DB00565,Cisatracurium besylate
,10223167,clearance,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.3,240364,DB00565,Cisatracurium besylate
,10223167,elimination half-life,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,26,240365,DB00565,Cisatracurium besylate
,9585798,ka,"Simulations were performed twice, with ka values of 0.1 (slow absorption) or 0.3 (rapid absorption) min-1.","Can bioavailability of low-variance drugs be estimated with an unpaired, sparse sampling design? ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585798/),1/[min],0.1,250359,DB00565,Cisatracurium besylate
,9585798,ka,"Simulations were performed twice, with ka values of 0.1 (slow absorption) or 0.3 (rapid absorption) min-1.","Can bioavailability of low-variance drugs be estimated with an unpaired, sparse sampling design? ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9585798/),1/[min],0.3,250360,DB00565,Cisatracurium besylate
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,93.25,250592,DB00565,Cisatracurium besylate
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,37.01,250593,DB00565,Cisatracurium besylate
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,64.56,250594,DB00565,Cisatracurium besylate
,22584638,Time of onset,"Time of onset was significantly shorter for rocuronium than cisatracurium for the adult and elderly groups (P = 0.000), but the variability of cisatracurium was significantly greater compared with rocuronium for the same age groups (93.25 vs 37.01 s in the adult group and 64.56 vs 33.75 s in the elderly group; P = 0.000).",Comparison of the variability of the onset and recovery from neuromuscular blockade with cisatracurium versus rocuronium in elderly patients under total intravenous anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584638/),s,33.75,250595,DB00565,Cisatracurium besylate
,26470914,onset time,"The onset time (i.e., the time to maximal neuromuscular block) was prolonged from 2.2 minutes to 5.0 minutes.",Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26470914/),min,2.2,264092,DB00565,Cisatracurium besylate
,26470914,onset time,"The onset time (i.e., the time to maximal neuromuscular block) was prolonged from 2.2 minutes to 5.0 minutes.",Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26470914/),min,5.0,264093,DB00565,Cisatracurium besylate
,26470914,time to maximal neuromuscular block,"The onset time (i.e., the time to maximal neuromuscular block) was prolonged from 2.2 minutes to 5.0 minutes.",Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26470914/),min,2.2,264094,DB00565,Cisatracurium besylate
,26470914,time to maximal neuromuscular block,"The onset time (i.e., the time to maximal neuromuscular block) was prolonged from 2.2 minutes to 5.0 minutes.",Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26470914/),min,5.0,264095,DB00565,Cisatracurium besylate
,31969113,onset time to maximal neuromuscular block,"The onset time to maximal neuromuscular block was prolonged from 2.07 ± 0.08 min to 4.03 ± 0.14 min, which indicated that the PD responses to cisatracurium were significantly delayed in the AR group (P < 0.05) compared to the control group.",Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969113/),min,2.07,273947,DB00565,Cisatracurium besylate
,31969113,onset time to maximal neuromuscular block,"The onset time to maximal neuromuscular block was prolonged from 2.07 ± 0.08 min to 4.03 ± 0.14 min, which indicated that the PD responses to cisatracurium were significantly delayed in the AR group (P < 0.05) compared to the control group.",Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969113/),min,4.03,273948,DB00565,Cisatracurium besylate
,31969113,K21,"A conventional two-compartment PK model showed a higher plasma concentration of cisatracurium among the AR group with markedly reduced intercompartment transfer rate (K12 = 0.19 ± 0.02 and K21 = 0.11 ± 0.01 in the AR group vs. K12=0.26 ± 0.01 and K21 = 0.19 ± 0.01 in the control group, P < 0.01) compared to the control group.",Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969113/),,0.11,273949,DB00565,Cisatracurium besylate
,31969113,K12,"A conventional two-compartment PK model showed a higher plasma concentration of cisatracurium among the AR group with markedly reduced intercompartment transfer rate (K12 = 0.19 ± 0.02 and K21 = 0.11 ± 0.01 in the AR group vs. K12=0.26 ± 0.01 and K21 = 0.19 ± 0.01 in the control group, P < 0.01) compared to the control group.",Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969113/),,0.26,273950,DB00565,Cisatracurium besylate
,31969113,K21,"A conventional two-compartment PK model showed a higher plasma concentration of cisatracurium among the AR group with markedly reduced intercompartment transfer rate (K12 = 0.19 ± 0.02 and K21 = 0.11 ± 0.01 in the AR group vs. K12=0.26 ± 0.01 and K21 = 0.19 ± 0.01 in the control group, P < 0.01) compared to the control group.",Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31969113/),,0.19,273951,DB00565,Cisatracurium besylate
